|
|
 |
|
Viewing report
|
|
|
|
Ranbaxy Generics Company Intelligence Report
Espicom Business Intelligence Ltd, March 2009, Pages: 32
This generics company report will help you to understand the dynamic and complex issues affecting the business of leading generic industry players.
This informative report provides an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.
Ranbaxy is India’s leading pharmaceutical company, one of only a handful so far to achieve international prominence. Manufacturing is conducted mainly in India, but also in other countries, such as Ireland. In 2007, the company began creating a major European operation in Romania, aimed at serving the rest of the EU.
The past few years have seen a concerted effort to break into the US and European markets, with a wide degree of success.
In 2004, revenues broke the US$1 billion mark for the first time. In 2007 Ranbaxy reported growth of 9.4%, with revenues totalling Rs66,353 million (US$1,683.2 million). Net profit rose by 53.3% to Rs7,901 million (US$200.4 million).
Ranbaxy is at the forefront of attempts to bring cheaper generic HIV/AIDS medicines to developing countries. It is keen to get approval for use under the US PEPFAR programme as well as by the WHO.
The company claims its long term aim is to move away from generics and into original drug research. This is partly spurred by the tightening of India’s patent laws which began in 2005. For the time being, however, generics will be the mainstay of the company’s revenues. The company has stated that the new patent law will not affect its product portfolio.
In June 2008, in a surprise move, Daiichi Sankyo announced plans to acquire Ranbaxy in a deal which valued Ranbaxy at US$8.5 billion. The acquisition was completed in October 2008.
In June 2008, Pfizer and Ranbaxy entered into an agreement to settle most of the long-running worldwide battles challenging Pfizer’s patents for atorvastatin. In April 2008, the firm entered into agreements with AstraZeneca to settle esomeprazole litigation.
Customers who bought this item also bought
Company Analysis - Ranbaxy Laboratories Limited
Ranbaxy Laboratories Limited
PharmaVitae 2002: Ranbaxy
RANBAXY LABORATORIES - World'Vest Base Dossier
Ranbaxy Laboratories Limited - SWOT Analysis
Ranbaxy Laboratories Limited Deals Briefing
Dr Reddy's Laboratories Generics Company Intelligence Report
PharmaVitae 2001: Ranbaxy
The Indian Pharmaceutical Industry 2009: Diversification, Expansion & Ambitions
Ranbaxy IMS Company Profile
Wockhardt Generics Company Intelligence Report
Actavis Generics Company Intelligence Report
|
|
|
|
